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L E T T E R  T O  T H E  E D I T O R
Daylight photodynamic therapy for actinic keratosis: Is it 
affected by the British weather?
Dear Editor, daylight photodynamic therapy (DPDT) is a simple, 
well-tolerated, convenient treatment option for patients with ac-
tinic keratosis (AK).1 It is particularly suitable for patients with field-
change AK on the face and scalp, for whom the pain and frequency 
of treatments can be problematic and limiting if treated with con-
ventional PDT. The pain experienced during DPDT is considerably 
lower than that encountered during conventional PDT as, after appli-
cation of photosensitizer pro-drug, there is continuous synthesis and 
photoactivation of low levels of protoporphyrin IX (PpIX) during the 
daylight exposure period.1,2 Treatment employs daylight exposure, 
which encompasses the combination of direct and diffuse sunlight 
outdoors during daytime, and in Northern Europe, this is generally 
from April to September. The daylight emission spectrum consists 
of ultraviolet, visible and infrared radiation, although it is largely the 
visible component that is of therapeutic importance in DPDT.
Early trials comparing daylight and conventional PDT for AK 
confirmed that DPDT was as effective as conventional PDT but was 
much less painful.3-5 We therefore introduced the first use of DPDT 
in Dundee, Scotland, in 2013 and reported on our early experience in 
2013-2015, with 64 patient treatments, showing clearance or good 
response in 73%, with very low pain scores and high levels of patient 
satisfaction.6
However, suitability of DPDT is subjected to favourable weather 
conditions, and we wanted to investigate whether the quality of the 
weather in the DPDT season (April-September) influenced treat-
ment outcomes following DPDT.
To answer this question, we compared our DPDT treatment out-
comes from 2016, 2017 and 2018. These are reported in Table 1, 
accompanied by a range of weather metrics, which provide informa-
tion on the “quality” of the DPDT season. Weather metrics were ob-
tained retrospectively from The Met Office7 (Leuchars, UK), with the 
exception of median temperatures on treatment days, which were 
recorded on the treatment day from the BBC Weather website.8 
Reported weather metrics do not include extent of cloud cover. 
Previous literature has indicated that successful daylight PDT can be 
performed on overcast days during the treatment season.2
We performed 142 treatments over 65 separate treatment days 
in 2018, double that of previous years. In 2018, there was much less 
rainfall, many more sunshine hours (Table 1) but the median treat-
ment day temperatures were similar. With more favourable weather 
conditions (less rain, more sunshine) over the course of our DPDT 
season, we were able to carry out more treatments and select more 
days that were suitable for treatment.
However, the response to treatment at 3 months postfinal 
treatment session was comparable across the three years despite 
the differences in rainfall and sunshine hours. One-third of patients 
achieved excellent outcomes in 2017 and 2018, and 63% had a mod-
erate/good response in 2018% vs 59% in 2017 and 69% in 2016. This 
similarity in efficacy is likely due to good treatment planning, with 
DPDT only being undertaken on days which we predict will have fa-
vourable weather conditions. The more frequent dry and sunny days 
in 2018 allowed us to treat more patients in that year but did not 
improve treatment outcomes. The similarity in the median treatment 
day temperature data evidences the careful selection of treatment 
days. Thus, whilst this is a retrospective review of our clinical data, it 
is reassuring for practitioners and patients as it indicates that, with 
good treatment planning, DPDT is an effective, well-tolerated, con-
venient treatment for patients with field-change AK, irrespective of 
the quality of the British summer weather.
KE Y WORDS
actinic keratosis, photodynamic therapy, weather
ACKNOWLEDG EMENTS
P O'Mahoney acknowledges financial support from Medi-lase 
(SC037390).
CONFLIC TS OF INTERE S T
SI has received conference travel expenses and honoraria from 
Galderma. PO and EE have received travel expenses from Galderma.
Iman Kotb1
Andrea Lesar2
Paul O'Mahoney3,4
Ewan Eadie2,4
Sally H. Ibbotson2,3,4
1Department of Dermatology, NHS Tayside, Ninewells Hospital 
and Medical School, Dundee, UK
2Photobiology Unit, NHS Tayside, Ninewells Hospital and 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Photodermatology, Photoimmunology & Photomedicine published by John Wiley & Sons Ltd
2  |     LETTER TO THE EDITOR
Medical School, Dundee, UK
3Photobiology Unit, University of Dundee, Dundee, UK
4Scottish Photodynamic Therapy Centre, Ninewells Hospital and 
Medical School, Dundee, UK
Correspondence
Ewan Eadie, Photobiology Unit, NHS Tayside, Ninewells 
Hospital and Medical School, Dundee DD1 9SY, UK.
Email: ewan.eadie@nhs.scot
ORCID
Paul O’Mahoney  https://orcid.org/0000-0003-3221-5105 
Ewan Eadie  https://orcid.org/0000-0002-7824-5580 
Sally H. Ibbotson  https://orcid.org/0000-0001-5685-752X 
R E FE R E N C E S
 1. Wiegell SR, Haedersdal M, Philipsen PA, et al. Continuous activation 
of PplX by daylight is as effective as and less painful than conven-
tional photodynamic therapy for actinic keratoses –a randomized, 
controlled single-blinded study. Br J Dermatol. 2008;158:740-774.
 2. Wiegell SR, Wulf HC, Szeimies R-M, et al. Daylight photodynamic 
therapy for actinic keratosis: an international consensus. J Eur Acad 
Dermatol Venereol. 2012;26:673-679.
 3. Wiegell SR, Hædersdal M, Eriksen P, Wulf HC. Photodynamic ther-
apy of actinic keratoses with 8% and 16% methyl aminolevulinate and 
home-based daylight exposure: a double-blinded randomized clini-
caltrial. Br J Dermatol. 2009;160:1308-1314.
 4. Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic ther-
apy with methyl aminolevulinate cream as a convenient, similarly 
effective, nearly painless alternative to conventional photodynamic 
therapy in actinic keratosis treatment: a randomized controlled trial. 
Br J Dermatol. 2014;171(5):1164-1171.
 5. Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic ther-
apy with methyl aminolevulinate cream is effective and nearly pain-
less in treating actinic keratoses: a randomised, investigator-blinded, 
controlled, phase III study throughout Europe. J Eur Acad Dermatol 
Venereol. 2015;29:2342-2348.
 6. Cordey H, Valentine R, Lesar A, et al. Daylight photodynamic therapy 
in Scotland. Scott Med J. 2017;62(2):48-53.
 7. Met Office. Met Office Historic Station Data. 2020. [Online]. https://
www.metof fice.gov.uk/resea rch/clima te/maps-and-data/histo ric-
stati on-data. Accessed April 02, 2020.
 8. BBC Weather. BBC Weather Forecast. 2020. [Online]. https://www.
bbc.co.uk/weath er/2650752. Accessed April 02, 2020.
TA B L E  1   Daylight photodynamic therapy treatment parameters and outcomes: Response to treatment, pain score, erythemal response, 
exposure time and dose
Year 2016 2017 2018
Median Dundee Temperature of 
treatment days (range) °C
15.5 (6-23) 15 (6-18) 15 (10-25)
Sunshine hours (April-September) 918.5 985.7 1131.5
Rainfall (mm, April-September) 321 380.6 239.2
Number of treatmentsa  71 64 142
Number of treatment days 31 34 65
Number of patients treated 26 22 43
Efficacyb  23% clear
31% good
38% partial
8% poor/no response
0% clear
32% excellent
41% good
18% moderate
9% slight/no response
0% clear
30% excellent
37% good
26% moderate
7% slight, no response
Median Pain Score (range) 0.7 (0-9) 1.9 (0-9) 0.7 (0-9)
Erythema 19% severe
63% mild to moderate
10% none
8% no data
10% severe
79% mild to moderate
6% none
5% no data
10% severe
78% mild to moderate
9% none
3% no data
Median Exposure Time (range) min 150 (120-450) 153 (75-375) 150 (60-285)
 aPatients may have multiple areas treated in one treatment. 
 bSemiquantitative scoring of efficacy (the wording of the grading system differed slightly in 2016 compared with 2017 and 2018). 2016: Clear = no/ 
minimal remaining disease, Good > 75% clearance, Partial > 50%-75%, Poor/no response <50% clearance. 2017/2018: Clear = no remaining visible 
disease, Excellent = minimal remaining disease, Good > 75% clearance, Moderate > 50%-75% clearance, Slight/no response <50% clearance. 
